Every other year screening for retinopathy

Article

Every other year screening for diabetic eye disease appears to be both safe and effective in patients with diabetes without retinopathy.

Every other year screening for diabetic eye disease appears to be both safe and effective in patients with diabetes without retinopathy, according to a report published online ahead of print by the British Journal of Ophthalmology.

Einar Stefánsson from the National University Hospital of Iceland and colleagues from the University of Iceland, reviewed 10-years experience of every other year screening for diabetics without retinopathy.

Of the 296 diabetic patients who had no diabetic retinopathy in 1994/1995, 172 did not develop retinopathy during the 10-year observation period. A total of 96 patients developed mild non-proliferative retinopathy, six developed clinically significant diabetic macular oedema, 23 developed pre-proliferative retinopathy and four developed proliferative diabetic retinopathy.

All the patients who did develop macular oedema or proliferative retinopathy had already been diagnosed with mild non-proliferative retinopathy and entered into an annual screening programme before sight threatening retinopathy developed. No patients experienced an undue delay in treatment.

According to the study, it would appear that screening for retinopathy in diabetic patients every other year is safe and effective and may help reduce unnecessary costs.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.